Alzheimer’s affects over seven million Americans—a number expected to double by 2050. New FDA-approved drugs and early-detection blood tests give families hope, but government red tape still stands in the way. The Market Institute believes patients and doctors—not bureaucrats—should decide when to use lifesaving innovations. Empowering access to modern treatments isn’t just good policy—it’s the compassionate choice.
Market Institute President Charles Sauer warns that the Federal Trade Commission’s latest attack on Amazon could undermine the very affordability concerns that policymakers say they want to address. In a new piece for RealClearMarkets, “Trump’s Read more…
In a new piece for RealClearMarkets, Market Institute Senior Fellow Norm Singleton argues that efforts to block the Paramount-Warner Bros. merger misunderstand how dramatically the entertainment market has changed. The Department of Justice’s Antitrust Division Read more…
In a new piece for RealClearMarkets, Market Institute President Charles Sauer warns that the Federal Trade Commission’s effort to police alleged ideological bias in artificial intelligence threatens both free speech and the competitive market that Read more…
In a new piece for RealClearMarkets, Market Institute President Charles Sauer takes on Vice President JD Vance’s call for a Republican economic agenda that moves beyond the “old free-market consensus” in favor of a more Read more…
Market Institute President Charles Sauer writes in the Boston Herald that Massachusetts has an opportunity to lead the fight against fraud, waste, and abuse in Medicare Advantage by addressing the incentives that encourage insurers to Read more…
Market Institute President Charles Sauer is calling on Congress to make Alzheimer’s early detection a priority when lawmakers return from August recess. In a new op-ed for the Daily Caller, Sauer argues that Congress should Read more…
6151 Fuller Court #8
Alexandria, VA 22310
The Market Institute
info@marketinstitute.org